Commentary · 21 Feb 2026
Conference abstractPublished 23 Jul 2018
Degradation of both β-catenin and RAS via targeting the Wnt/β-catenin pathway is an ideal approach for colorectal cancer treatment
Yonsei University, South Korea
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Interaction between the Wnt/beta-catenin and the Ras-ERK pathways, two major transforming pathways, have been posited. However, molecular mechanisms and cooperative roles of these two pathways are poorly understood. Both APC and KRAS mutations synergistically promote cellular transformation and tumor growth, attributed to activation of the RAS-ERK pathway via activation of the Wnt/ Ã?²-catenin signaling. One key event in this crosstalk is the stabilization of RAS, especially mutant KRAS, by APC loss. Stabilization of both Ã?²-catenin and RAS plays a critical role in the synergistic transformation, and both Ã?²-catenin and RAS levels are highly increased in CRC patient tissues. Epidermal growth factor receptor (EGFR), a direct transcriptional target of the Wnt/Ã?²-catenin signaling pathway, is also overexpressed in human CRC, and plays a role in the synergistic tumorigenesis. Therefore, inhibition of both the Wnt/Ã?²-catenin and EGFR-RAS-ERK pathways, especially by reducing levels of the proteins elevated in CRC, could be an ideal approach for the treatment of human CRC. This concept for an ideal therapeutic approach has been proved by small molecules destabilizing both Ã?²-catenin and RAS by activation of GSK3Ã?² via targeting the Wnt/Ã?²-catenin pathway. GSK3Ã?² activated by the small molecules induce phosphorylation and subsequent polyubiquitin-dependent proteasomal degradations of both Ã?²-catenin and Ras and subsequent transcriptional suppression of EGFR overcome current limitation of the insensitiveness of the EGFR targeting therapies such as cetuximab attributed by a K-Ras mutation of patients. Moreover, these small molecules effectively suppress activaiton of cancer stem cell activated through aberrancies of the Wnt/ Ã?²-catenin and Ras-ERK pathways. Recent Publications: 1. Cha P H, Cho Y H, Lee S K, Lee J H, Jeong W-J, et al. (2016) Small molecule binding of the axin-RGS domain promotes Ã?²-catenin and Ras degradation. Nature Chemical Biology 12: 593âÂ?Â?600. 2. Kim H Y, Choi S, Yoon J H, Lim H J, Lee H, et al. (2016) Small molecule inhibitors of Dishevelled-CXXC5 interaction are new drug candidates for bone anabolic osteoporosis therapy. EMBO Molecular Medicine 8:375âÂ?Â?387. 3. Lee S H, Kim M Y, Kim H Y, Lee Y M, Kim H S, et al. (2015) The dishevelled-binding protein cxxc5 negatively regulates cutaneous wound healing. Journal of Experimental Medicine 212(7):1061âÂ?Â?80. 4. Kim H Y, Yoon J Y, Yoon J H, Cho K W, Lee S H, et al. (2015) CXXC5 is a negative-feedback regulator of the Wnt/Ã?²- catenin pathway involved in osteoblast differentiation. Cell Death and Differentiation. 22(6):912âÂ?Â?20. 5. Moon B S, Jeong W J, Park J, Kim T I, Min D S, et al. (2014) Oncogenic K-Ras accelerates cancer stem cell activation via aberrant Wnt/beta-catenin signaling. JNCI-Journal of the National Cancer Institute 106(2):373.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Cancer Science & Therapy.
Perspective · 21 Feb 2026
Finding Potential Passerini Adducts for Anticancer Drug Development
Perspective · 21 Feb 2026
Head and Neck Cutaneous Squamous Cell Carcinoma with Perineural Invasion
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalCancer Science & Therapy
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Kang-Yell Choi”
